Company Encyclopedia
View More
name
Bioxcel Therap
BTAI.US
BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally dissolving film formulation of dexmedetomidine in Phase 3 trial for the treatment of agitation associated with bipolar disorders, schizophrenia, and Alzheimer’s disease, as well as opioid use disorder, alcohol use disorder with comorbid post-traumatic stress disorder, and acute stress disorder; and its immune-oncology candidate, BXCL701, which is an investigational oral innate immune activator that has completed Phase 1b/2a trial for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors. In addition, the company engages in the development of BXCL502 for the treatment of stress-related neuropsychiatric symptoms in dementia and other stress-related disorders; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, which has the potential to address apathy and aggression in dementia.
1.945 T
BTAI.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking296/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE78.16%A
    • Profit Margin-9070.61%E
    • Gross Margin88.78%A
  • Growth ScoreE
    • Revenue YoY-66.96%E
    • Net Profit YoY3.92%C
    • Total Assets YoY-8.39%E
    • Net Assets YoY-3.84%D
  • Cash ScoreD
    • Cash Flow Margin-1.10%D
    • OCF YoY-66.96%E
  • Operating ScoreE
    • Turnover0.02E
  • Debt ScoreE
    • Gearing Ratio298.52%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights

    Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) breached their fiduciary duties to shareholders. The firm encourages current BioXcel shareholders, particularly long-term ones, to contact them to discuss their legal rights and options, which may include seeking corporate governance reforms or financial awards. Halper Sadeh LLC handles such actions on a contingent fee basis, emphasizing that shareholder involvement can enhance company transparency and value.

    Business Wire·
    US
    BTAI
    +0.96%
    Business Wire·
    US
    BTAI
    +0.96%

    BioXcel Therapeutics Q3 2025 Financial Results and Clinical Program Updates

    BioXcel Therapeutics has released its Q3 2025 financial results, reporting a decrease in net revenue from IGALMI® but also significantly reduced cost of goods sold. The company increased R&D expenses due to heightened clinical trial activity while decreasing SG&A expenses. BioXcel Therapeutics is advancing its late-stage clinical programs, including the SERENITY At-Home Phase 3 Safety Trial and the TRANQUILITY In-Care Phase 3 Trial, and plans to submit a supplemental New Drug Application (sNDA) in early Q1 2026 for the at-home use of IGALMI®.

    TradingView·
    US
    BTAI
    +0.96%
    TradingView·
    US
    BTAI
    +0.96%

    BioXcel Therapeutics shares are trading lower after the company reported worse-than-expected Q3 financial results.

    benzinga_article·
    US
    BTAI
    +0.96%
    benzinga_article·
    US
    BTAI
    +0.96%

    Bioxcel Therap | 10-Q: FY2025 Q3 Revenue Misses Estimate at USD 98 K

    LB filings·
    US
    BTAI
    +0.96%
    LB filings·
    US
    BTAI
    +0.96%

    BioXcel Therapeutics Q3 Loss Wides, Shares Update On Clinical Development Programs

    BioXcel Therapeutics, Inc. (BTAI) reported a widened net loss of $30.9 million for Q3 2025, compared to $13.7 million last year. Product revenues fell to $98,000 from $214,000. The company updated on its clinical programs, noting positive results for BXCL501 in agitation treatment and plans to submit a supplemental New Drug Application for IGALMI in early 2026. BTAI shares are down 5.94% in pre-market trading at $1.9.

    rttnews·
    US
    BTAI
    +0.96%
    rttnews·
    US
    BTAI
    +0.96%
    © 2025 Longbridge｜Disclaimer